Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer

AR-V7-expressing metastatic prostate cancer is an aggressive phenotype with poor progression-free survival (PFS) and overall survival (OS). Preliminary evidence suggests that AR-V7-positive tumors may be enriched for DNA-repair defects, perhaps rendering them more sensitive to immune-checkpoint bloc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Boudadi, Karim, Suzman, Daniel L., Anagnostou, Valsamo, Fu, Wei, Luber, Brandon, Wang, Hao, Niknafs, Noushin, White, James R., Silberstein, John L., Sullivan, Rana, Dowling, Donna, Harb, Rana, Nirschl, Thomas R., Veeneman, Brendan A., Tomlins, Scott A., Wang, Yipeng, Jendrisak, Adam, Graf, Ryon P., Dittamore, Ryan, Carducci, Michael A., Eisenberger, Mario A., Haffner, Michael C., Meeker, Alan K., Eshleman, James R., Luo, Jun, Velculescu, Victor E., Drake, Charles G., Antonarakis, Emmanuel S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2018
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6033362/
https://ncbi.nlm.nih.gov/pubmed/29983880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25564
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge